Warbicin Inhibitors Targeting GLUT ATP-Binding Domain for Selective Cancer Cell Glucose Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer therapies targeting the Warburg effect often suffer from adverse side-effects due to universal importance of glucose catabolism in all cell types, and existing glucose uptake inhibitors fail to selectively inhibit overactive glucose uptake in cancer cells without affecting healthy cells.
Innovation Solution
Development of inhibitors that specifically target hexokinase-dependent glucose carrier-mediated glucose uptake, such as Warbicin A and its analogs, which resemble adenosine and bind into the ATP-binding domain of glucose carriers, effectively inhibiting glucose uptake in cancer cells without compromising basal glucose uptake in healthy cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If glucose uptake inhibitors are used to target the Warburg effect in cancer cells, then glucose uptake in cancer cells is inhibited, but basal glucose uptake in healthy cells is also affected causing adverse side-effects
Solution Approach 1:
The patent applies local quality by designing inhibitors that specifically target the unique structural features of cancer cell glucose carriers (GLUT1, GLUT3, GLUT4) with altered conformational states, rather than blocking all GLUT carriers universally. The inhibitors exploit local structural differences in the ATP-binding domain of cancer-specific GLUT isoforms to achieve selective inhibition, allowing healthy cells with different GLUT isoform expressions to maintain normal glucose uptake.
Solution Approach 2:
The patent employs parameter changes by developing inhibitors that respond to specific biochemical parameters unique to cancer cells, such as elevated ATP concentrations and altered membrane potential in highly metabolically active cancer cells. The inhibitors are designed to bind with higher affinity under these specific parametric conditions, enabling selective targeting of cancer cells while sparing healthy cells with different metabolic parameters.
2Productivity
If existing glucose uptake inhibitors are used, then glucose uptake is inhibited, but selectivity between cancer cells and healthy cells is insufficient
Solution Approach 1:
The patent applies segmentation by dividing the GLUT carrier family into distinct functional groups based on tissue-specific expression patterns and kinetic properties. The inhibitors are designed to segmentally target specific isoforms (GLUT1, GLUT3, GLUT4) that are overexpressed in cancer cells, while leaving other isoforms (GLUT2, GLUT5) that are important for healthy cell function unaffected. This segmented approach enables precise selectivity in inhibiting cancer cell glucose uptake.
Solution Approach 2:
The patent uses ATP as an intermediary mechanism, designing inhibitors that require ATP binding to the GLUT carrier for effective inhibition. Since cancer cells have elevated ATP levels due to their high metabolic rate and Warburg effect, this intermediary mechanism provides an additional layer of selectivity. Healthy cells with normal ATP concentrations are less affected by these ATP-dependent inhibitors, thereby improving selectivity.
3Reliability
If broad-spectrum glucose catabolism inhibition is used to treat cancer, then cancer cell growth is inhibited, but toxicity increases due to universal importance of glucose metabolism
Solution Approach 1:
The patent applies dynamics by designing inhibitors that exploit the dynamic metabolic state of cancer cells. The inhibitors are structured to bind more effectively to GLUT carriers in their cancer-specific conformational states, which are dynamically maintained by the Warburg effect and high glycolytic flux. This dynamic binding mechanism ensures that inhibition is most effective in cancer cells with high metabolic activity, while healthy cells with different metabolic dynamics are spared from toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These inhibitors selectively reduce glucose uptake in cancer cells, restoring normal growth patterns in yeast mutants and inhibiting proliferation in cancer cells, while showing no toxicity in mice, thus offering a targeted approach to treating cancers and conditions associated with overactive glycolytic flux.
Implementation Method 1
inhibitors that specifically target hexokinase-dependent glucose carrier-mediated glucose uptake, such as Warbicin A and its analogs, which resemble adenosine and bind into the ATP-binding domain of glucose carriers
Data Source
AI summary
The present invention relates to inhibitors of hexokinase-dependent glucose carrier-mediated glucose uptake (Warbicins) that can be used to inhibit proliferation of cancer cells and other cells with an overactive glucose uptake and catabolism, i.e. the Warburg effect. The Warbicins of the invention are used in the prevention or treatment of cancers or other conditions associated with or aggravated by an overactive glycolytic flux, such as pulmonary hypertension, cardiac hypertrophy, heart failure, atherosclerosis, Alzheimer's diseases, multiple sclerosis, polycystic kidney disease, tuberculosis, diabetic kidney disease and autoimmune diseases.